Sharemaestro Newsreel

Zura Bio Ltd SEC Filing (Aug 13, 2026)

This article reports on an SEC Form 144 filing by Zura Bio Ltd on August 13, 2026. The filing indicates a proposed sale of 51,000 shares of common stock, acquired through a stock option exercise, with an aggregate market value of $287,043.30, to be …

Praxis Precision Medicines (PRAX): Orbis, Allan Gray disclose 5.5% ownership stake

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly disclosed a 5.5% ownership stake in Praxis Precision Medicines (PRAX), amounting to 1,529,788 shares of common stock as of June 30, 2026. Orbis holds the majority with 1,526,680 shares, while Allan Gray …

UBS Maintains Schrodinger(SDGR.US) With Hold Rating, Maintains Target Price $19

UBS has reiterated its Hold rating on Schrodinger (SDGR.US) and maintained its target price at $19. This indicates that the firm does not anticipate significant upward or downward movement for the stock in the near term, based on its current analysis.

Artivion (AORT): Nomura entities report 6.5% beneficial stake in 13G/A

Nomura Asset Management International Inc. and Nomura Investment Management Business Trust have reported a combined 6.5% beneficial ownership in Artivion, Inc., totaling 3,184,974 shares of common stock. This filing, a Schedule 13G/A, indicates shared voting and dispositive power over these shares, calculated based on …

Cormorant Asset Management (BIOA) discloses 5.38% BioAge Labs ownership stake

Cormorant Asset Management, LP and Bihua Chen have disclosed a 5.38% beneficial ownership stake in BioAge Labs, Inc. (BIOA), as reported in an amended Schedule 13G filing. This ownership amounts to 2,390,605 shares of common stock, with both shared voting and dispositive power. The …

Kaplan Fox Investigates Fulcrum Therapeutics After 51% Stock Plunge Following Pociredir Program Halt

Kaplan Fox & Kilsheimer LLP has initiated an investigation into Fulcrum Therapeutics (NASDAQ: FULC) following a 51% stock drop. The plunge occurred after Fulcrum unexpectedly halted its pociredir program for sickle cell disease due to FDA concerns over its benefit-risk balance. The investigation will …

Neumora Therapeutics Releases Q2 2026 Financial Results

Neumora Therapeutics (NMRA) reported a diluted loss per share of $0.23 for Q2 2026, representing a net loss of $43.1 million. The clinical-stage biopharmaceutical company narrowed its per-share loss by 30.3% year-over-year compared to Q2 2025. This performance is typical for biopharma companies in …

Spruce Biosciences (SPRB) sees AWM Investment disclose 5.1% equity stake

Cormorant Asset Management (ANL) discloses 3.98M Adlai Nortye ADS position

Is Alcon (SWX:ALC) Below Fair Value On Mixed Earnings And RxSight News?

Alumis' (ALMS) "Neutral" Rating Reaffirmed at HC Wainwright

Luigi Mangione Pleads Guilty in US Case Over CEO Killing

Luigi Mangione pleaded guilty in a federal case over the fatal shooting of UnitedHealth Group executive Brian Thompson in December 2024. View Comments

Bleichroeder (MDXH) reports 31.6M-share, 33.2% holding in MDxHealth

Bleichroeder LP and related parties have reported a 33.2% beneficial ownership in MDxHealth SA, totaling 31,648,563 Ordinary Shares. This significant stake was accumulated for investment purposes, including a recent purchase of over 24 million shares in a registered direct offering at $0.454 per share …

U.S. Physical Therapy (NYSE:USPH) Trading Down 4.8% - Here's Why

Mangione Admits to Killing Healthcare CEO Brian Thompson

Luigi Mangione pleaded guilty to federal stalking charges related to the fatal shooting of UnitedHealth Group Inc. executive Brian Thompson. Mangione admitted on Friday in New York federal court that he shot and killed Thompson on Dec. 4, 2024. He faces life in prison. …

OptimizeRx Corp (OPRX) gains 6.7% institutional holder in Kennedy Capital

Kennedy Capital Management LLC has reported a beneficial ownership of 1,248,899 shares of OptimizeRx Corp (OPRX) common stock, representing a 6.7% stake. The firm, based in St. Louis, Missouri, holds sole voting and dispositive power over these shares, establishing itself as a significant institutional …

Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase

Three Pfizer insiders executed transactions directly on the heels of the drugmaker’s second-quarter earnings report. Continue Reading

Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3% - Should You Sell?

Sana Biotechnology (NASDAQ:SANA) shares dropped 5.3% to $3.4750 on Friday, with trading volume significantly below average. Despite the dip, analyst sentiment is mixed but leans positive, with an average target price of $9.50, although one analyst recently downgraded the stock to "Sell." The company …

Revenue per share of SCYNEXis, Inc. – DUS:135

This article displays the "Revenue per share" information for SCYNEXIS, Inc. (DUS:135) on the TradingView platform. It shows the period, value, change, and percentage change for this financial metric. The content also notes that the market is closed with no trades.

BAX|Baxter International Inc|Price:26.685|Chg%:-0.365

Alvotech (Z45) Q2 2023 Earnings Report - Results, Call & Slides

Alvotech (Z45) released its Q2 2023 earnings report, showing an EPS beat of +€0.07 with an actual EPS of -€0.05 against a consensus of -€0.12. However, the company missed revenue expectations significantly, reporting €3.81M against an expected €36.49M. The earnings announcement was on August …

Adicet Bio: A Cheap Gamma Delta T-Cell Play (NASDAQ:ACET)

Adicet Bio presents a differentiated allogeneic gamma delta CAR-T platform targeting autoimmune diseases, trading below cash value with a pivotal readout for prula-cel in lupus nephritis imminent in Q3 2026. Early data showed a 50% complete renal response and a clean safety profile. The …

Cormorant Asset Management (RLYB) now reports 0% beneficial ownership of Rallybio

Cormorant Asset Management, LP and Bihua Chen have reported that they no longer beneficially own any shares of Rallybio Corp (RLYB), marking their ownership at 0%. This disclosure, filed as an amendment to a Schedule 13G, indicates zero sole or shared voting or dispositive …

Genmab A/S (GMAB): Orbis and Allan Gray report 5.3% beneficial ownership stake

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly reported a beneficial ownership stake of 5.3% in Genmab A/S (GMAB), totaling 3,328,505 Ordinary Shares. This includes both direct Ordinary Shares and American Depositary Shares (ADS). The filing indicates that while they …

(PRAX) and the Role of Price-Sensitive Allocations

This article provides a detailed AI-driven analysis of Praxis Precision Medicines Inc. (NASDAQ: PRAX), highlighting a strong overweight bias across all time horizons. It outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report …

Bright Minds Biosciences (DRUG): Cormorant Asset Management reports 9.17% ownership stake

Cormorant Asset Management, LP and Bihua Chen have reported a significant ownership stake of 9.17% in Bright Minds Biosciences Inc. This beneficial ownership translates to 900,000 Common Shares out of 9,812,061 shares outstanding as of May 15, 2026. The reporting persons share voting and …

Vistagen (VTGN) narrows quarterly loss, eyes FDA path after mixed fasedienol data

Vistagen (VTGN) reported a narrower net loss of $13.0 million for Q1 FY2027, an improvement from $15.1 million in the prior-year quarter, largely due to increased revenue and reduced R&D and G&A expenses. While its lead drug fasedienol missed its primary endpoint in the …

Susquehanna entities (QURE) disclose 3.34M-share, 4.8% position in uniQure

A group of affiliated Susquehanna entities has filed an amended Schedule 13G/A, reporting a collective beneficial ownership of 3,339,231 Ordinary Shares, representing 4.8% of uniQure N.V.'s outstanding shares. This stake includes options to buy shares held by Susquehanna Securities, LLC and SIG Brokerage, LP. …

TransMedics Group, Inc. Investor News: Rosen Law Firm

The Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). The firm is encouraging shareholders of TransMedics Group to visit its website or contact them for more information regarding …

OPKO Health (NASDAQ:OPK) Trading Down 5.4% - Here's What Happened

OPKO Health (NASDAQ:OPK) shares experienced a 5.4% drop in mid-day trading, closing at $1.325 with significantly lower trading volume than average. Despite the stock decline, the company recently reported better-than-expected quarterly earnings, with an adjusted loss of $0.01 per share against an anticipated $0.08 …

Cormorant Asset Management (MLTX) discloses 4.35% MoonLake Immunotherapeutics stake

Cormorant Asset Management, LP and Bihua Chen have disclosed a 4.35% beneficial ownership stake in MoonLake Immunotherapeutics (MLTX), totaling 3,205,433 Class A ordinary shares. This stake, reported via a SCHEDULE 13G/A filing, indicates shared voting and dispositive power over the shares and is based …

Innovative Eyewear Inc Q2 2026: Revenue $1.01M, EPS $(0.26) — 10-Q Summary

Innovative Eyewear Inc (LUCY) reported Q2 2026 results showing a significant revenue increase to $1.01M, a 74% year-over-year rise, driven by strong unit volume and expanded retail presence. The company also narrowed its net loss to $1.67M from $2.11M in Q2 2025, with diluted …

Butterfly Network Stock (BFLY) Opinions on Q2 Earnings and Institutional Interest

Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?

AbbVie's neuroscience franchise experienced strong growth in the first half of 2026, with sales reaching $6.1 billion, driven by key drugs like Vraylar, Ubrelvy, Qulipta, and Botox Therapeutic, and the rapid uptake of Vyalev. The company anticipates further growth from the potential approval of …

Vera Therapeutics Shares Up 9.7% as $425,000 Drug Launch Puts Focus on Cash Reserves

Brandes Investment Partners reports 14.9% Utah Medical Products (UTMD) stake